Does a cardiovascular event change adherence to statin treatment in patients with type 2 diabetes? A matched cohort designDe Vries, D., Denig, P., Vegter, S., Bos, H. J., Postma, M. J. & Hak, E., 1-Oct-2014, In : Pharmacoepidemiology and Drug Safety. 23, S1, p. 319-320 2 p.
Research output: Contribution to journal › Meeting Abstract › Academic
Background: Statin treatment is associated with a reduction in the risk of cardiovascular events. To be effective, adherence is essential but this may be influenced by the occurrence of a cardiovascular event while being on treatment. Objectives: To assess the effect of an apparent first event on statin adherence rates in type 2 diabetes patients. Methods: A matched cohort study was conducted among type 2 diabetes patients initiating statin treatment for primary prevention in the Groningen University IADB.nl pharmacy database. Index patients who had a drug-treated cardiovascular event (index date) after statin initiation were matched to a reference patient without such an event with similar gender, age at statin initiation, initiation date, follow-up period and adherence level before the event. Medication proxies were used to identify apparent events. Adherence rates were measured as percentages of days covered (PDC), relative risks with 95% confidence intervals (95%CI) were calculated for shifts in adherence levels (nonadherent, partial-adherent, full-adherent) around the index date. Adherence rates around the index date were evaluated using Wilcoxon signed ranks tests and Mann-Whitney U Tests. Results: We could match 375 of the 855 eligible index patients. Index patients had on average a PDC of 81% after the index date; reference patients had a PDC of 71% (P
|Number of pages||2|
|Journal||Pharmacoepidemiology and Drug Safety|
|Publication status||Published - 1-Oct-2014|
- statin (protein), human, patient, non insulin dependent diabetes mellitus, pharmacoepidemiology, risk management, diabetic patient, primary prevention, cohort analysis, drug therapy, confidence interval, Wilcoxon signed ranks test, university, follow up, gender, data base, risk factor, rank sum test, pharmacy, risk